The below Parliamentary question was asked by Andrew Gwynne on 2016-02-01.
To ask Mr Chancellor of the Exchequer, how many companies benefiting from the patent box are (a) UK and (b) non-UK domiciled pharmaceutical manufacturers.
Mr David Gauke
The information is not held in the form requested. The estimated amounts of Patent Box relief can be found at the link below:
“
The below Parliamentary question was asked by Andrew Gwynne on 2016-02-02.
To ask the Secretary of State for Health, what meetings (a) he, (b) the Minister for Public Health and (c) his special advisers had with representatives of the People Against Sugar Tax campaign in the last six months.
Jane Ellison
Details of all Ministerial meetings with external stakeholders are published quarterly in arrears on the GOV.UK website. The latest publication which covers meetings between July and September 2015 is available at:
Information for October to December 2015 will be published at the end of March.
“
The below Parliamentary question was asked by Andrew Gwynne on 2016-02-03.
To ask the Secretary of State for Communities and Local Government, what assessment he has made of the benefits of granting permitted development rights to mobile network masts up to 50 metres in height in non-protected areas.
Brandon Lewis
The review of how the planning system in England can further support the delivery of mobile connectivity sought views on the planning changes made in 2013 including 4G deployment and the case for taller ground based masts. The outcome will be announced in due course.
The below Parliamentary question was asked by Andrew Gwynne on 2016-02-10.
To ask the Secretary of State for Communities and Local Government, what assessment he has made of the long-term financial sustainability of councils with low council tax bases.
Mr Marcus Jones
In reaching the funding decisions announced at the recent Spending Review, the Government had regard to a wide range of issues that might impact on local government over the spending period. The analysis took into account a range of financial and economic factors as well as changes in demand.
When allocating funding through the local government finance settlement, the Government has taken into account the resources available to local authorities including the ability of authorities to raise funding locally through Council Tax.
The Government has made it clear that redistribution of funding between local authorities will continue under the 100% business rates retention system, to be brought in by 2020. The redistribution system will take into account differing Council Tax bases. The Government will hold a Fair Funding Review to consider the appropriate funding needs of different types of areas.
The below Parliamentary question was asked by Andrew Gwynne on 2016-02-24.
To ask the Secretary of State for Health, how much of the £390 million funding referred to in paragraph 0.5 of his Department’s paper, Infected blood: reform of financial and other support, published in January 2016, was spent in each year to date; and what the average spend per recipient in each such year was.
Jane Ellison
The Department only holds finance data for payments under the Schemes back to 2007. This information is provided below.
2014-15 £22,278,096
2013-14 £27,043,569
2012-13 £22,052,458
2011-12 £27,192,232
2010-11 £39,805,667
2009-10 £22,461,057
2008-09 £19,240,337
2007-08 £20,532,461
The figures above include the annual payments to those with HIV and hepatitis C stage 2, and the lump sum payments made on joining the scheme and progressing to hepatitis C stage 2. The fluctuation in amounts between the years reflects the variance in number of people newly coming forward or progressing to hepatitis C stage 2 in each year.
The payments to individuals included both discretionary and non-discretionary payments, data on which is only held by the trusts and funds. Therefore, the Department is unable to estimate the levels of individual payments.
The below Parliamentary question was asked by Andrew Gwynne on 2016-03-01.
To ask the Secretary of State for Health, with reference to page 15 of the interim report of the Accelerated Access Review, published October 2014, what recent discussions he has had on the implementation of new models of pricing and reimbursing drugs; when he anticipates implementing such new models; what discussions he has had with (a) his Department’s officials and (b) external organisations on the applicability of such models to drugs targeting the genetically validated target PCSK9; and if he will make a statement.
George Freeman
The Accelerated Access Review, chaired by Sir Hugh Taylor, will make recommendations to government on reforms to accelerate access for National Health Service patients to innovative medicines and medical technologies making our country the best place in the world to design, develop and deploy these products. The terms of the reference for the review focus on faster access to innovations, which may include drugs that target genetically validated targets such as PCSK9 and BCL2.
The below Parliamentary question was asked by Andrew Gwynne on 2016-03-08.
To ask the Secretary of State for Health, what proportion of office space owned or occupied by (a) his Department and (b) its executive agencies is currently unused.
Jane Ellison
The proportion of office space owned or occupied by the Department and its executive agencies which is currently unused is (a) 0% and (b) 1.37 %.
The Department’s executive agencies are Public Health England and the Medicines and Healthcare products Regulatory Agency. The vacant space is leased by the Medicines and Healthcare products Regulatory Agency and will be released on 31 March 2016.
The below Parliamentary question was asked by Andrew Gwynne on 2016-03-17.
To ask the Secretary of State for Health, if he will place copies of all responses received to NHS England’s consultation on the new Cancer Drugs Fund in the Library.
George Freeman
NHS England has operational responsibility for the Cancer Drugs Fund and has advised that it currently has no plans to publish all responses received on its consultation on the future of the Fund. An analysis of the consultation responses was published on 25 February 2016 and is available at:
www.engage.england.nhs.uk/consultation/cdf-consultation
“
The below Parliamentary question was asked by Andrew Gwynne on 2016-04-11.
To ask the Secretary of State for Health, how much was spent by clinical commissioning groups on palliative care for (a) children and young people and (b) adults in each of the last three years.
Ben Gummer
The information is not available in the format requested. Such information as is available is shown in the following table.
Clinical Commissioning Group (CCG) Expenditure on End of Life Care, 2013/14 (£ millions)
|
All CCGs in England |
472.75 |
Source: Programme Budgeting Collection, NHS England
Notes:
“
The below Parliamentary question was asked by Andrew Gwynne on 2016-05-18.
To ask the Secretary of State for Education, what monitoring her Department undertakes of the (a) allocation, (b) spending and (c) outcomes of pupil premium funding at (i) maintained schools and (ii) academy trust schools.
Mr Sam Gyimah
The conditions of grant for the pupil premium make clear that its purpose is to raise the attainment of disadvantaged pupils. School leaders are best placed to decide how to spend the pupil premium in line with this policy and the needs of their pupils. Schools are not prevented from using the pupil premium to fund capital projects or from carrying over funding between years.
The Department for Education supports schools to make evidence-based decisions through the work of the Education Endowment Foundation, established to identify and promote effective practice in raising the attainment of disadvantaged pupils. The Department does not monitor how Academies and maintained schools spend the pupil premium but instead holds them to account for the outcomes of eligible pupils through the publication of data in performance tables and Ofsted inspection.
Where concerns are raised about the performance of an academy then they are addressed by the Regional School Commissioner with responsibility for that area. The Department also takes seriously any concerns about the financial management of a school. We are aware of the findings of the Ofsted report on Audenshaw School relating to its use of the pupil premium, following an inspection in February 2016. We are also aware that the Hon. Member, Andrew Gwynne, has met the Regional Schools Commissioner for Lancashire and West Yorkshire, Vicky Beer, on a number of occasions to discuss his concerns about Audenshaw School Academy Trust. The Department has carefully reviewed all the information provided on this matter and has identified no grounds to take further action.